COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

December 15, 2020
Well-Known Oncogenic Mutations ErbB2/Her2 May Also Play A Role in Leukemogenesis

Activating point mutations in ErbB/Her2 receptor tyrosine kinases have an infamous role in promoting oncogenesis across several different cancers, including breast and lung.  Heterodimer activation of the ErbB2/ErbB3 oncogenic unit induces cancer cell proliferation via PI3K/AKT signaling pathways.  However, its role in leukemogenesis is still largely unknown.  Clinical Proteomic Tumor Analysis Consortium (CPTAC) inves
December 8, 2020
In Case You Missed It: CPTAC Junior Investigator Spotlight (Part 2)

In case you missed it, this final article (part 2 of 2) in the Investigator Spotlight Series, developed and written by Dr.
December 1, 2020
First Large-scale, Multicenter Proteogenomic Analysis Offers New Insights Into Pediatric Brain Tumor Biology

Data reported can guide new therapeutic avenues for pediatric patients

A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer-related deaths in children. The results could help physicians more accurately identify different types of tumors and methods for treating them.
November 18, 2020
Proteogenomics Enhances the Identification of Therapeutic Vulnerabilities in Breast Cancer

Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard and other institutions have applied powerful proteogenomics approaches to better understand the biological complexity of breast cancer.
November 3, 2020
Evaluating Biomarkers in Metastatic Breast Cancer Bone Biopsies Without Decalcification

In a recent publication in the journal Clinical Chemistry,  CPTAC investigators from Fred Hutchinson Cancer Research Center described a robust technique for evaluating biomarker expression of key receptors in patients with breast cancer bone metastasis using non-decalcified bone biopsies in imm
October 20, 2020
CPTAC Study Identifies Unique Linkage of Glycosylation to Ovarian Cancer

Protein glycosylation, the enzymatic process that attaches glycans or sugar molecules to proteins, plays a crucial role in cancer development processes, such as cell-cell adhesion, cell growth, ligand-receptor binding, and tumor metastasis. Aside from phosphorylation, other protein modifications have not been investigated in large-scale proteomic studies.
October 13, 2020
Improved BASIL Workflow Provides Precise and Robust Protein Profiling for Single-Cell Analysis

Almost 18 months ago, CPTAC researchers from theIntegrative Omics Group at Pacific Northwest National Laboratory (PNNL), developed a stream-lined technique to increase the sensitivity of peptide phospho-group identification during mass spectral analysis.  The solution, called the ‘
October 4, 2020
In Case You Missed It: CPTAC Junior Investigator Spotlight (Part 1)

In case you missed it, this third article (part 1 of 2) in the Investigator Spotlight Series, developed and written by Dr.
September 14, 2020
New Proteogenomic Data Release for CPTAC Lung Squamous Cell Carcinoma Discovery Study!

Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study!  Because LSCC accounts for about 30% of all lung cancers and has a ~20% 5-year survival rate, it’s imperative that cancer

September 8, 2020
AutoRT - Using Peptide Retention Time Prediction to Accurately Determine Quality of Peptide Identification

In a recent issue of Nature Communications, Clinical Proteomics Tumor Analysis Consortium (CPTAC) researchers from Bing Zhang’s lab at Baylor College of Medicine describe a new bioinformatics software tool developed to evaluate the quality of variant peptide identifications.  Using a deep learning algorithm, the software

Pages

more

View all News and Announcements